Current treatment status-Undergoing active treatment-Progressive despite treatment - Page 7 of 29 Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor

Which low-intensity chemotherapy is most effective for patients with classical Hodgkin lymphoma receiving stem cell transplantation?

Which low-intensity chemotherapy is most effective for patients with classical Hodgkin lymphoma receiving stem cell transplantation?

Posted by on May 10, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study compared the effectiveness of three low-intensity chemotherapy combinations to treat patients with classical Hodgkin lymphoma (HL) following stem cell transplantation (SCT). There were no significant differences between the three chemotherapy types in terms of patients’ survival and relapse. Some background...

Read More

Tucatinib in combination with trastuzumab and capecitabine for HER2 positive metastatic breast cancer

Tucatinib in combination with trastuzumab and capecitabine for HER2 positive metastatic breast cancer

Posted by on May 6, 2020 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of tucatinib in combination with trastuzumab and capecitabine in patients with HER2 positive metastatic breast cancer who have had disease progression with other treatments.   This study concluded that this treatment combination was safe and...

Read More

Have the outcomes of stem cell transplants for young patients with relapsed or refractory Hodgkin lymphoma improved over time?

Have the outcomes of stem cell transplants for young patients with relapsed or refractory Hodgkin lymphoma improved over time?

Posted by on Apr 25, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined if the outcomes of stem cell transplants (SCT) have improved for young patients with relapsed or refractory Hodgkin lymphoma (HL) over time. The results showed that SCT has improved the survival rate and reduced the relapse rate of HL in young patients in recent years. Some background While initial treatment is...

Read More

How effective is BV-DHAP chemotherapy to treat patients with relapsed or refractory Hodgkin lymphoma?

How effective is BV-DHAP chemotherapy to treat patients with relapsed or refractory Hodgkin lymphoma?

Posted by on Apr 25, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined the effectiveness and safety of the chemotherapy combination BV-DHAP for patients with relapsed or refractory Hodgkin lymphoma (HL). The authors found that BV-DHAP was an effective and safe treatment to progress patients to high-dose chemotherapy and stem cell transplant. Some background During treatment, some...

Read More

Long-term outcomes of daratumumab with lenalidomide and dexamethasone in relapsed or unresponsive multiple myeloma

Posted by on Apr 16, 2020 in Multiple Myeloma | 0 comments

In a nutshell The study compared the use of lenalidomide (Revlimid) and dexamethasone (Decadron) alone and with daratumumab (Darzalex) in patients with relapsed or unresponsive multiple myeloma (MM). The study showed that patients receiving all three drugs had better treatment response and survival. Some background MM is a type of cancer that affects...

Read More

Second-line tyrosine kinase treatment in patients with chronic myeloid leukemia who have failed first-line treatment

Posted by on Apr 3, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate second-line tyrosine kinase inhibitor (TKI) treatment in patients with chronic-phase chronic myeloid leukemia (CP-CML) who had failed first-line TKI treatment.  This study concluded that these patients have good outcomes with second-line TKI treatment.   Some background Tyrosine kinase...

Read More

Reviewing treatment options for patients with recurrent classical Hodgkin’s lymphoma

Reviewing treatment options for patients with recurrent classical Hodgkin’s lymphoma

Posted by on Mar 16, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This article reviews treatment options for patients with classical Hodgkin's lymphoma (cHL) that came back (relapsed) after chemotherapy. This study found that targeted therapies are becoming more prevalent and that patient outcomes have improved. Some background cHL is a cancer of white blood cells called lymphocytes....

Read More

Have outcomes improved for patients with Hodgkin’s lymphoma who relapse after a stem cell transplant?

Have outcomes improved for patients with Hodgkin’s lymphoma who relapse after a stem cell transplant?

Posted by on Mar 16, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the long-term outcomes of patients with classical Hodgkin’s lymphoma (cHL) that came back after an autologous stem cell transplant (autoSCT). This study found that advancements in treatment have helped improve survival outcomes for patients. Some background Chemotherapy is usually the first-line...

Read More

The comparison of outcomes of two salvage therapies in patients with relapsed or unresponsive acute myeloid leukemia

Posted by on Mar 4, 2020 in Leukemia | 0 comments

In a nutshell The study evaluated the effectiveness of two salvage therapies – mitoxantrone (Novantrone), etoposide (Etopophos), and cytarabine (Cytosar-U) also known as MEC and cladribine (Leustatin), cytarabine, filgrastim (Neupogen), and mitoxantrone also known as CLAG-M, for treating relapsed/refractory acute myeloid leukemia...

Read More

The effects of blinatumomab in patients with relapsed or unresponsive acute lymphoblastic leukemia in outside of clinical trials

Posted by on Feb 24, 2020 in Leukemia | 0 comments

In a nutshell The study evaluated the safety and effectiveness of blinatumomab (Blincyto) in patients with relapsed or unresponsive B-acute lymphoblastic leukemia (B-ALL) outside of clinical trials. The authors found that blinatumomab was safe and effective to treat such patients in real-world medical practice. Some background Relapsed...

Read More

Evaluating the R-BAC regimen for patients with MCL that stops responding to TKI therapy

Evaluating the R-BAC regimen for patients with MCL that stops responding to TKI therapy

Posted by on Feb 22, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of the R-BAC (rituximab, bendamustine, cytarabine) regimen for patients with relapsed or unresponsive mantle cell lymphoma (MCL). This study concluded that R-BAC was effective for these patients. Some background MCL is a rare but aggressive type of non-Hodgkin’s lymphoma (NHL). After initial...

Read More